GlassScriptPhysician profile
Derek Pineda
NPI 1659750636
$37,956.23
in general payments reported to CMS, 2019-2025
23 companies · $5,069 in 2025
The $5,069 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,567 · 2022: $9,308 · 2023: $6,108 · 2024: $11K · 2025: $5,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,600 · Travel and Lodging: $2,818 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,250 · Consulting Fee: $390 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,923.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,600.00 |
| Travel and Lodging | $2,818.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,250.00 |
| Consulting Fee | $390.00 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,033.61 | 2021-2025 | Lokelma, Wainua, Andexxa |
| Medtronic, INC. | $5,825.69 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Ffrangio |
| Shockwave Medical, INC | $4,038.36 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $1,706.14 | 2021-2024 | Xarelto |
| Tactile Systems Technology INC | $1,644.31 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Amgen INC. | $1,431.25 | 2021-2025 | Repatha, Repatha |
| Abiomed | $1,236.59 | 2023-2025 | Impella |
| Boston Scientific Corporation | $1,215.04 | 2021-2025 | General - Balloon Catheters, Synergy, Opticross |
| Scpharmaceuticals INC. | $883.53 | 2024-2025 | |
| Abbott Laboratories | $796.22 | 2021-2025 | Amplatzer Amulet, Mitraclip, Coroflow |
| Novartis Pharmaceuticals Corporation | $669.30 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $509.94 | 2022-2025 | Camzyos, Eliquis |
| Cardiva Medical, INC. | $412.89 | 2024-2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade 6/7f Vcs, Optowire |
| Cordis US Corp. | $361.77 | 2022-2025 | Mynx Control Venous, Mynx Control |
| Novo Nordisk INC | $340.15 | 2021-2024 | Wegovy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $291.17 | 2022-2024 | |
| Esperion Therapeutics, INC. | $193.99 | 2025 | Nexletol |
| Chiesi USA, INC. | $190.20 | 2022-2023 | Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $53.76 | 2024 | Arcalyst |
| Terumo Medical Corporation | $52.50 | 2024 | Metacross Otw, Azur Cx Detachable |
| Edwards Lifesciences Corporation | $31.58 | 2025 | |
| Heartflow, INC. | $24.25 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $13.99 | 2024 | Bard Silicone Uretero-Intestinal Anastomosis Urinary Diversion Stent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Pineda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.